Cynata Therapeutics Receives Proposed WHO Generic Name for Cymerus Cell Therapy
WHO proposes “pixenstrocel” as the generic name for Cynata’s Cymerus cell therapy
Cynata Therapeutics (ASX: CYP) has been informed by the World Health Organization (WHO) that “pixenstrocel” has been selected as the proposed International Nonproprietary Name (INN) for its Cymerus iPSC-derived MSCs, following an application by the company. The proposed INN is expected to be published in WHO Drug Information List 136 in early 2027, with a four-month comment period to follow and final confirmation anticipated around May 2027.
Once confirmed, pixenstrocel will be used to describe Cymerus iPSC-derived MSCs across regulatory documents, scientific literature, promotional material, product labelling and information leaflets. This represents a formal step in Cynata’s pathway toward regulatory approval, rather than a final milestone.
When big ASX news breaks, our subscribers know first
What is an INN and why does it matter for biotech investors?
An International Nonproprietary Name is the official generic name assigned by the WHO to an active pharmaceutical ingredient. It serves as the universal reference used across all regulatory, scientific and commercial contexts globally, regardless of the trade name a company eventually applies to a product.
For Cynata, it is important to understand the distinction between the INN and the company’s existing product codes. The codes (CYP-001, CYP-004, and CYP-006TK) identify specific final product formulations, while “pixenstrocel” identifies the active agent itself. The INN will not replace these codes but will be used alongside them. The three current product codes and their respective formulations are:
- CYP-001 — intravenous infusion (acute graft versus host disease)
- CYP-004 — intra-articular injection (osteoarthritis)
- CYP-006TK — topical wound dressing (diabetic foot ulcers)
In due course, trade names will be selected for each product. At that point, those trade names will be used alongside the INN in place of the existing product codes.
INN assignment carries meaningful weight for investors because it is a prerequisite step in the regulatory approval process. A product reaching this stage signals that it is progressing toward commercial readiness, even while clinical trials remain ongoing.
Building toward regulatory approval while trials advance
Nuket Desem, Director of Regulatory and Scientific Affairs, Cynata Therapeutics
“As we await the results of the Australian Phase 3 trial of CYP-004 in osteoarthritis and the multinational Phase 2 trial of CYP-001 in acute graft versus host disease, in parallel we are pursuing a number of important activities to progress towards our ultimate goal of seeking regulatory approval to market our products. Selection of an INN is one of these important activities, and we look forward to the final confirmation from the WHO next year.”
The comment underscores that INN selection is one of several concurrent preparatory activities Cynata is advancing while trial results are pending. The company is not waiting for outcomes before progressing commercial readiness steps.
Beyond the two headline trials referenced, the pipeline includes a Phase 2 trial of CYP-001 in GvHD under a cleared US Food and Drug Administration (FDA) Investigational New Drug (IND) application, and a Phase 1/2 trial of CYP-001 in kidney transplantation patients, reflecting the regulatory breadth the company has already established.
| Product | Indication | Trial Phase | Geography | Status |
|---|---|---|---|---|
| CYP-004 | Osteoarthritis | Phase 3 | Australia | Awaiting results |
| CYP-001 | Acute GvHD | Phase 2 | Multinational | Ongoing |
| CYP-001 | Kidney transplantation | Phase 1/2 | Not specified | Ongoing |
The next major ASX story will hit our subscribers first
What comes next for pixenstrocel and the Cymerus platform
The near-term milestones on the INN pathway are as follows:
- Publication of proposed INN “pixenstrocel” in WHO Drug Information List 136 — early 2027
- Four-month public comment period opens following publication
- Final INN confirmation expected around May 2027
Following confirmation, trade name selection will proceed. Trade names will eventually replace the existing product codes in commercial and promotional contexts, operating alongside the confirmed INN.
The pixenstrocel name applies broadly across the Cymerus platform, which is built on iPSC-derived MSCs and designed to enable scalable, consistent manufacturing without reliance on multiple tissue donors. All current pipeline candidates share this common biological foundation. Investors should note that while the INN milestone is a meaningful step in the regulatory process, it represents a procedural progression rather than a commercial approval.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers staying ahead of market-moving developments. Click the “Free Alerts” button at StockWire X to get the next big healthcare announcement the moment it drops.